sophageal cancer is a highly malignant disease and the recurrence rate after surgery is extremely high. 2 As surgical resection alone rarely results in long -term survival, efforts are now focused on combined multimodality treatments in an attempt to improve local control and eliminate micrometastases present at the time of surgery. Although the combination of radiation and anticancer drugs, 5 -fluorouracil (5 -FU ) 3 and cisplatinum, is most frequently used in the current therapy, therapeutic efficacy has not been satisfactory established due to their side effects 4 and the acquisition of resistance. 5 Resistance to 5-FU is associated with reinforcement of phosphorylation 6, 7 and reduced activity levels of enzymes involved in pyrimidine nucleotide synthesis. 8 We, therefore, attempted to overcome the 5-FU resistance by modification of 5-FU phosphorylation. Escherichia coli uracil phosphoribosyltransferase ( UP; EC 2.4.2.9 ) is a pyrimidine salvage enzyme that catalyzes the synthesis of uridylate from uracil and 5 -phosphoribosyl-a -1 -diphosphate. 9 , 10 We previously reported that UP gene transfer was able to sensitize gastric cancer cells to low concentrations of 5-FU in vitro and in vivo. 1, 11 Recently, several reports have shown that double gene transfer, by the addition of the herpes simplex virus thymidine kinase (TK ) gene, was able to enhance the antitumor activity of single gene transfer. 12 ± 14 Moreover, nontransduced dividing cells located in the vicinity of TK -transduced tumor cells can also be killed through a bystander effect. 15 We, therefore, developed a recombinant adenovirus vector (AxCA.UT ) containing a UP /TK fusion gene (UT ) to assess its effect on the antitumor effect of UP gene transfer. We determined the protein expression and enzyme activity of both UP and TK. We then examined the antitumor effect and bystander effect of AxCA.UT treatment in in vitro and in vivo studies.
MATERIALS AND METHODS
Human esophageal cancer cell lines and culture conditions TE -2, established from a poorly differentiated squamous cell carcinoma of human esophagus, was generously provided by Dr. Nishihira (University of Tohoku, Japan ). T.Tn, established from a moderately differentiated squamous cell carcinoma, 16 was obtained from ATCC ( Rockville, MD ). Cells were maintained and propagated in RPMI 1640 medium ( Nissui, Tokyo, Japan ), supplemented with 10% heat -inactivated fetal bovine serum.
Generation and confirmation of recombinant adenoviral vector
A recombinant adenoviral vector containing UP and TK genes expressed under the CAG promoter 17 was con-structed essentially according to the procedure described previously. 18 The UP gene (GenBank accession no. X57104) was synthesized from the E. coli K12 strain DH5a genomic DNA by polymerase chain reaction (PCR ) using the following primers: no. 969, 5
H -GCGAATTC-CACCATGAAGATCGTGGAAGTCAAACAC -3 H and no. 970, 5
H -GGCGGATCCTTATTTCGTACCAAAGATTTTG-TCACCGG -3
H . The resultant PCR product was digested with EcoRI /BamHI and subcloned into the EcoRI /BamHI sites of pBluescript SK II( + ) (Stratagene, La Jolla, CA ), resulting in pSK II( + )/UP. The EcoRI/ BamHI fragment ( 649 bp ) from pSK II( + ) /UP was then cloned into the EcoRI/ BglII sites of the pCAGGS, resulting in pCA /UP. pAxCA.UP was generated by ligation of the CA.UP expression cassette (the blunted SalI/HindIII fragment, $2.9 kbp) into the SwaI site of pAd -cw. 19 Plasmid pPNT, which contains the TK gene in an expression cassette with the murine phosphoglycerate kinase -1 gene promoter and poly( A ) signal sequences, was kindly provided by Dr. Rudnicki (Whitehead Institute, MIT ). A BglII fragment ( $2070 bp ) from pPNT containing the TK gene fragment with the coding region and its own poly( A ) signal sequence ($1789 bp from BglII at nt458 of GenBank J0224 to PvuII at nt2247 of J0224 ) and the poly( A ) signal sequence fragment from the murine phosphoglycerate kinase-1 gene ( $279 bp from PstI to BglII; GenBank no. X76682 ) were ligated into the blunted EcoRI site of pCAcc, 20 resulting in pCA.TK. pAxCA.TK was generated by ligation of the CA /TK expression cassette ( ClaI fragment ) into the ClaI site of pAx -cw. 19 The UP coding region followed by a linker and the 5 H end of the TKcoding sequence was amplified by PCR using the following primers: no. 969, 5
H -GCGAATTCCACCAT-GAAGATCGTGGAAGTCAAACAC -3 H and no. 996, 5 HGGGAATTCacgcgtGTTGATGGCAGGGGTACGAAGCC-ATACCCCCTCCTCC -ACCGCCCCCGCCGGATCCTCC-3 H . The MluI site (ACGCGT ) in the no. 996 primer corresponds to the MluI site in the 5 H coding region of the TK DNA sequence. The resultant PCR product ( $710 bp ) was digested with EcoRI and subcloned into pBluescript SK II( + ), resulting in pSK II( + ) /UP / linker, the sequence of which was confirmed by DNA sequencing. The 353-bp KpnI/MluI fragment from the pSK II( + ) /UP / linker, and the MluI/HindIII fragment of the TK gene construct from the pPNT were ligated into the alkaline phosphatase ± treated KpnI/HindIII fragment of pCAUP, resulting in pCA.UT. The predicted amino acid sequence of the UP gene plus TK fusion gene (UT ) product is 595 amino acids long, consisting of the 208 amino acids of the UP gene, an 11-amino -acid linker ( Gly± Gly ±Ser± Gly ±Gly ± Gly ± Gly± Gly ±Gly± Gly ±Gly), and the 376 amino acids of the TK gene. pAxCA.UT was generated by ligation of the CA.UT expression cassette (blunted SalI/HindIII fragment ) into the SwaI site of pAx -cw. The resultant viral vectors were termed AxCA.UT ( adenovirus containing UP /TK fusion gene ), AxCA.UP ( adenovirus containing UP gene ), and AxCA.TK ( adenovirus containing TK gene ). AxCA.Z ( adenovirus containing lacZ gene ) was used as a control vector in this study. The recombinant adenoviruses were propagated with 293 cells, and the titers of infective viral particles were evaluated by the standard plaque -forming assay on 293 cells.
-Galactosidase transduction assay
To assess gene transduction efficiency of the recombinant adenoviral vectors into the esophageal cancer cells, monolayers of the two cell lines were treated with AxCA. Z for 1 hour and cultured for a further 48 hours. Cells were washed with phosphate -buffered saline ( PBS ) and fixed in PBS containing 1 mM /L MgCl 2 and incubated for 1 hour in PBS containing 5 mM / K 3 Fe( CN ) 6 , 5 mM/K 4 Fe( CN ) 6 , 1 mM/L MgCl 2 , and 1 mg / mL 5 -bromo -4 -chloro-3-indolyl --Dgalactopyranoside ( X -gal; Wako, Tokyo, Japan ). Increasing doses of AxCA.Z, from 0 to 1000 multiplicity of infection ( MOI ), were used to maximize gene transfer. The percentage of cells expressing -galactosidase was determined by scoring total cells and stained cells under the microscope on triplicate dishes.
Enzymatic activity of UP in AxCA.UT -transduced cells Enzymatic activity of UP was measured as described previously. 21 T.Tn cells ( 5Â10 7 ) were infected with AxCA.UP, AxCA.UT, or AxCA.Z. After 48 hours, the cells were resuspended in PBS and soluble cell extracts were prepared by sonication. The assay mixture contained Tris ± HCl (10 M; pH 7.5 ), MgCl 2 (10 M), phosphoribosylpyrophosphate ( 10 M ), unlabelled 5 -FU (2 M), and [
3 H]5-FU (12.5 mCi /mL; 0.875 M). The cell lysate ( 10 g ) was incubated with the reaction mixture at 378C. After incubation for 0, 5, 10, and 15 minutes, the aliquots ( 90 L ) were boiled for 3 minutes to terminate the reaction. The aliquots were then applied to DEAE cellulose to separate 5 -FU and 5-fluorouridylate and were chromatographed in methanol:-water (1:1 ). After drying and autoradiography, the spots corresponding to uracil and UMP were cut out, and their radioactivity was measured using a liquid scintillation counter. The background of the UMP spot at 0 minute was estimated from a blank reaction without cell lysate. The enzymatic activity of UP was calculated as the difference between the radioactivity of cell lysate and the nonspecific radioactivity of the blank.
Western blot analysis
TK protein expression was confirmed by Western blot analysis after AxCA.Z, AxCA.UP, AxCA.TK, and AxCA.UT infection using T.Tn cells. Samples were collected 48 hours after infection as described above and resuspended in the appropriate volume of loading buffer [ Tris ±HCl ( 125 M), glycerol ( 10% ), sodium dodecyl sulfate (1% ), 2-mercaptoethanol ( 1% ), bromophenol ( 0.5% ), pH 6.8 ]. Then, the samples ( 10 g of protein per lane in 20 mL ) were applied to a 10% polyacrylamide sodium dodecyl sulfate gel using standard procedures. 22 Proteins were transfered to a membrane and nonspecific binding sites were blocked by incubating the membrane in Tris -buffered saline (TBS ), containing Tween (0.1% ) and nonfat dried milk ( 5% ) for 1 hour at room temperature. Primary antibody incubations were carried out in TBS containing Tween (0.1% ), using polyclonal antisera directed
SHIMIZU, SHIMADA, OCHIAI, ET AL: UPRT/HSV-TK FUSION GENE THERAPY FOR ESOPHAGEAL CANCER against TK (kindly provided by Dr. W. Summers, Yale University ). After washing in TBS containing Tween ( 0.1% ), the secondary antibody incubation was carried out using a horseradish peroxidase ±conjugated donkey antirabbit antibody (Amersham, Arlington Heights, IL) for 1 hour at room temperature. Subsequent protein detection was performed using the enhanced chemiluminescence (ECL ) detection system (Amersham ).
In vitro 5 -FU and ganciclovir ( GCV ) sensitivity
Cells were seeded at a density of 3000 cells/well in 96-well plates and were infected at 500 MOI with either AxCA.Z, AxCA.UP, AxCA.TK, or AxCA.UT for 1 hour and then cultured with various concentrations of 5-FU, GCV, or both drugs and were then were cultured at 378C for a further 5 days. Cell viability was evaluated using the MTT assay 23 which was tested in a quadruplicate manner at each time point; cells were incubated in 100 L of MTT solution [MTT (50 g ), glucose (0.1 mg ), MgSO 4 (0.08 M ), NaHCO 3 ( 225 g ), HEPES (0.5 M/100 L of PBS ( À ) ] for 1 hour at 378C, and shaken for 10 minutes after addition of ethanol ( 100 L ) to solubilize the formazan formed. The optical densities were read on an automated spectrophotometric plate reader at a wavelength of 540 nm. The results were expressed as viability of the cells in plates containing drugs as a percentage of viability in the corresponding drug -free controls.
In vitro bystander effect
The in vitro bystander effect was evaluated by mixing AxCA.UT-infected T.Tn cells with parental T.Tn cells using ratios of 100:0 (100% ) and 50:50 (50% ). In brief, 1500 T.Tn cells per well were infected with AxCA.UT. After 48 hours, the infected cells were rinsed extensively to remove uninfected viruses and were mixed with equal numbers of uninfected cells from other plates. The cells were incubated at 378C for 5 days in the presence of various concentrations ( 0.03± 1000 M ) of 5 -FU or GCV. Cell viability was evaluated by the MTT assay, as described above.
In vivo tumor treatment
To evaluate the ability of AxCA.UT intratumoral injection plus systemic 5 -FU and GCV administration to suppress tumor growth in vivo, subcutaneous tumors were established by injecting 2Â10 6 T.Tn cells or 5Â10 6 TE -2 cells into the flank of athymic BALB /c, nu /nu mice ( 7 weeks old; Charles River Japan, Tokyo, Japan ). For TE -2 tumor establishment, 5 mg / body of cyclophosphamide was intraperitoneally injected 1 day before tumor transplantation to suppress xenogeneic reaction. On day 7 (T.Tn ) or day 14 ( TE -2 ), when the tumor volumes were 40± 50 mm 3 , mice were randomized in a blind manner into three groups. Then, the viral suspension containing 1Â10 9 pfu of AxCA.Z, AxCA.UP, or AxCA.UT was injected into the tumor on three successive days. From the first day of viral injection, mice were treated with intraperitoneal injections of 5-FU (10 mg / kg /d ) and GCV (25 mg /kg /d ) up to 10 days. Tumor size was measured twice per week using calipers and was calculated as 0.4ÂlengthÂwidth 2 (mm 3 ).
Statistical analysis
Results were expressed as the mean SD. Comparison between two groups were made with the Mann -Whitney U test using Stat View software (Abacus Concepts, Berkeley, CA ). A P value of less than .05 was considered statistically significant.
RESULTS

Efficiency of gene transfer via adenoviral vectors into human esophageal cancer cells
In both cell lines, 50% transduction efficiency was obtained at 60 MOI and 90% transduction efficiency was obtained at 500 MOI ( Fig 1 ) . Based on these results, we used 500 MOI as optimal condition for further study.
UP enzymatic activity in human esophageal cancer cells 
Detection of TK proteins in transduced T.Tn cells
Parental AxCA.Z -infected and AxCA.UP -infected cells were completely negative for TK protein expression ( Fig 2,  lanes 1, 2, 3 ). On the other hand, TK protein at an apparent molecular size of 44.3 kDa was seen in AxCA.TK -infected cells (Fig 2, lane 4) , whereas a large band ( 67.0 kDa ) was seen in AxCA.UT-infected cells (Fig 2, lane 5 ) . The difference between these two molecules (44.3 vs. 67.0 kDa ) was the result of the difference between the TK and UT fusion proteins. A single band of the TK protein, which was expressed on AxCA.UT-infected cells, was thought to result from a UT fusion enzyme heterodimer. The expression level of TK in AxCA.UT-infected cells was lower than in AxCA.TK -infected cells.
Sensitization of human esophageal cancer cells to 5 -FU and GCV in vitro
T.Tn ( Fig 3, A and B ) and TE -2 (Fig 3, C and D ) cells were infected at 500 MOI of AxCA.Z, AxCA.UP, AxCA.TK, or AxCA.UT viruses and then were then cultured in the media containing various concentrations of 5 -FU or GCV. At 500 MOI, AxCA.UP and AxCA.UT revealed minor cytotoxicity on both cell lines ( about 10% of growth suppression), whereas AxCA.TK showed high cytotoxicity ( 40% of growth suppression in T.Tn and TE -2 cells). The ability of AxCA.UP and AxCA.UT to increase sensitivity to 5-FU was almost identical in T.Tn ( Fig 3A ) and TE -2 cells ( Fig 3C ) . The IC 50 value for 5 -FU in T.Tn cells was reduced from 100 to 6 M by AxCA.UP and AxCA.UT transduction. In TE -2 cells, the IC 50 value for 5-FU was also reduced from 60 to 7 M by AxCA.UP transduction and to 2 M by AxCA.UT transduction. Growth inhibition activity of GCV treatment was observed with AxCA.UT and AxCA.TK transduction, but not with AxCA.UP transduction. The IC 50 values for GCV treatment, combined with AxCA.UT transduction in T.Tn and TE -2 cells, were 70 and 10 M, respectively. Although the IC 50 values for GCV treatment were < 10 M in both cell lines, cytotoxic activity was observed without GCV treatment, mainly resulting from the toxicity of AxCA.TK viral vector itself. Because the cytotoxic activity of the AxCA.TK virus itself was much higher than those of AxCA.UP and AxCA.UT, we decided to use only AxCA.UP as a control virus for further study.
Sensitization of human esophageal cancer cells by AxCA.UT virus to 5 -FU plus GCV combination treatment in vitro
Cytotoxicity assays were performed to compare the effect of 5 -FU plus GCV combination treatment (Fig 4 ) on AxCA.UT-transduced cells with solely 5 -FU or GCV treatment alone. The drug concentrations used in this combination therapy were taken from Figure 3 ( IC 70 of the cell lines were as 1 M of 5 -FU and 3 M of GCV ). T.Tn ( Fig 4A ) and TE -2 ( Fig 4B ) cells were infected at 500 MOI with AxCA.Z, AxCA.UP, or AxCA.UT and then were then cultured in media containing 5 -FU, GCV, or both at the above concentrations. In AxCA.UP -infected T.Tn cells, no difference in cytotoxicity was observed between 5-FU treatment and 5-FU plus GCV combination treatment (68% cell survival in each group ). No cytotoxic effect was observed in the GCV treatment alone. In AxCA.UT-infected T.Tn cells, 5-FU plus GCV combination treatment showed a significantly greater cytotoxic effect (43% cell survival ) than either 5-FU or GCV treatment (70% cell survival each ) (P < .0001 ). In AxCA.UT-infected TE -2 cells, 5-FU plus GCV combination treatment also enhanced cytotoxicity.
In vitro bystander effect of AxCA.UT transduction combined with 5 -FU / GCV on human esophageal cancer cells
We then sought to determine whether the AxCA.UT /5 -FU / GCV system is associated with a bystander effect; i.e., whether sensitivity to 5-FU and GCV occurs in non-
Control
AxCA.lacZ AxCA.UP AxCA.TK AxCA.UT transduced wild -type cells adjacent to UT-expressing cells. We compared the percentage of cell survival between 100% AxCA.UT-infected cells and 50% AxCA.UT-infected cells treated with various concentrations of 5 -FU (Fig 5, A and C ) or GCV ( Fig 5, B and D ) . At each drug concentration ( 0.03± 1000 M 5 -FU ), cytotoxic activity was identical in 100% infected cells and 50% infected cells (Fig 5, A and C ) . A similar tendency was observed in the cells treated with GCV ( Fig 5, B and D ) . In both cell lines, when AxCA.Ztransduced cells were mixed with parental cells, the percentage of cell survival remained at the same level as the control value in the presence of 5 -FU plus GCV.
In vivo effect of AxCA.UT transduction combined with 5 -FU / GCV on established human esophageal cancers
To evaluate in vivo cytotoxic effects, PBS, AxCA.UP, or AxCA.UT was injected into transplanted tumors of T.Tn cells, together with systemic administration of 5 -FU plus GCV. Tumor volumes were 40± 50 mm 3 at time of injection. Both AxCA.UP and AxCA.UT treatment significantly suppressed tumor growth on day 16 ( P= .0067 vs. UP; P < .0001 vs. UT ) (Fig 6A ) . AxCA.UT-treated tumors were significantly smaller than AxCA.UP -treated tumors on 21 days of treatment ( P= .013 ). Of the 12 treated mice, in each group, none of the transplanted tumors disappeared in the AxCA.UPtreated group, whereas two disappeared in the AxCA.UT-treated group. A similar cytotoxic effect was observed in TE -2 transplanted tumors. The AxCA.UTtreated tumors were significantly smaller than the AxCA.UP -treated tumors ( day 50; P= .0047 ) ( Fig 6B ) . Among the 12 treated mice in each group, only one transplanted tumor disappeared in the AxCA.UP -treated group, whereas six disappeared in the AxCA.UT-treated group. 
DISCUSSION
Based on the potential of double gene combination therapy to enhance the effect of single gene therapy, in this study, we have created a recombinant adenoviral vector that expresses a UP plus TK fusion gene. The main finding of this study is that UP plus TK fusion gene therapy increased the antitumor effect of UP gene therapy in two human esophageal carcinoma cell lines ( T.Tn and TE -2). The UT fusion gene was shown to encode a bifunctional enzyme possessing both UP -and TK -specific activities and to increase the cytotoxic effect of 5-FU as well as GCV in esophageal carcinoma cells in vitro and in vivo. It is noteworthy that each modality alone can achieve an IC 50 level of esophageal carcinoma cell kill at the optimal concentration at which it is usually used as an anticancer or antiviral agent.
The AxCA.UT-transduced tumor cells revealed sensitization to low concentrations of 5 -FU and GCV. In the tumor cells, 5 -FU requires enzymatic conversion to a nucleotide, ribosylation, and phosphorylation to exert its cytotoxic activity. Among three independent pathways of 5 -FU phosphorylation, 5 -FU may be converted to fluorouridine by uracil ribosyltransferase, and then to 5-fluorouridylate by uridine kinase. In AxCA.UP -transduced cells, 5-FU is converted directly to 5 -fluorouridylate. Sensitization of the two esophageal carcinoma cell lines in response to low concentrations of 5 -FU treatment with AxCA.UT infection may target the phosphorylation step as one of the most important steps in 5 -FU cytotoxicity. The important finding of this study was that 5 -FU dosage could be reduced to avoid clinical adverse effects. The plasma 5-FU level typically ranges from 200 to 1000 M ( C max ) with bolus administration and 0.5 ±8.0 M ( steady -state levels) with continuous infusion in clinical situations. 24, 25 As a result, concerning IC 50 values in Figure 3 ( 6 M in T.Tn cells and 7 M in TE -2 cells ), the effect of AxCA.UP infection with 5-FU treatment alone may be insufficient for a good response in esophageal cancer treatment.
A typical plasma GCV level is 25.88 M (C max ) with intravenous injection, and ranges from 2.75 to 22.4 M ( steady -state levels ) with twice -daily infusion; 26 thus, GCV treatment may also be insufficient for a good response. However, AxCA.UT infection with the 5 -FU / GCV combination treatment produced a good response ( Fig 4 ) . Moreover, our in vivo study also showed a good response using clinical dosages of both drugs (Fig 6 ) . The difference in cell survival between UP and UT cells following treatment with the drug combination seems modest compared to the large apparent differences in antitumor activity shown in Figure 6 . This could be the result of the difference between the 5 -FU /GCV concentration in the tumor and that in the media of the in vitro experiment. A similar tendency was observed in our previous work, showing the effect of a UP /5 -FU system. 1 A limitation of our study is that the cytotoxic effect of AxCA.TK vector itself was much greater than that of AxCA.UP and AxCA.UT vectors (Fig 3 ) . This toxicity was possibly due to the high level of TK protein expression by AxCA.TK infection, as has been reported by others. 27 Because the cytotoxic effect of AxCA.UT was well regulated with GCV treatment and comparable to the cytotoxic effect of AxCA.TK, we decided that AxCA.UT vector was superior to AxCA.TK vector. A second limitation of our in vivo study is that controls to assess whether there is any differential effect of AxCA.UP compared to AxCA.UT in the absence of drug treatment were not performed. There was no difference in the percentage of cell survival between AxCA.Z, AXCA.UP, and AxCA.UT infection with 0.01 M of 5 -FU (Fig 3) . Moreover, in our previous report, there was no difference in tumor suppression between AxCA.UP and AxCA.Z infection in the absence of drug treatment.
1 As a result, we believed that the enhanced tumor suppression seen in AxCA.UT treatment was the result of the additive effect of TK /GCV combination treatment, and not the result of fusion protein expression itself.
A bystander effect was also demonstrated in this study. The bystander effects of TK gene therapy with GCV treatment 28, 29 and UP gene therapy with 5 -FU treatment 1 required gap junction intercellular communication. In the present study, direct cellular contact was also required for the bystander effect ( data not shown ). From the results of our study, the cytotoxic effect of 50% transduction was the same as that with 100% transduction. As local endoscopic intratumoral injection will be applied for esophageal cancer gene therapy in clinical trials, it will be difficult to transduce all cancer cells in the tumor by lowefficiency in vivo gene transduction. A bystander effect of AxCA.UT gene therapy may be useful for such solid tumor treatment. Important advantages of combination gene therapy were reported by Rogulski et al 12 and Uckert et al 13 as a synergistic effect in cytosine deaminase plus TK therapy. However, in AxCA.UT infection with 5-FU /GCV treatment, an additive, rather than a synergistic effect, was observed in human esophageal cancer cells compared to AxCA.UP infection with 5 -FU treatment. This may be explained by the fact that: (i ) AxCA.UT-transduced tumor cells were already highly sensitive to 5 -FU treatment alone and that this effect could only be improved slightly by the additive utilization of the TK /GCV mechanism; and ( ii ) TK protein expression level in AxCA.UT-infected cells was slightly lower, possibly due to limitations of the fusion gene construct. A fusion at the 5 H end of TK may have reduced TK enzymatic efficiency. As a result, this UT / GCV /5 -FU system may be a useful model, but it remains to be determined whether further genetic manipulations may be needed to preserve the activity of the TK protein.
Even if the combined cytotoxic effects of these modalities were simply additive, it should be possible to achieve significant cell kill when these two modalities are used simultaneously.
Furthermore, it has been reported that the use of cytokine genes or prodrug gene, IL -12, 30 GM -CSF, 31 or cytosine deaminase, 12, 13, 32 combined with the TK /GCV system, can reinforce the effect of the TK /GCV system. Similarly, we might expect the same reinforcement of the effect of UT with the 5-FU /GCV system when adding the cytosine deaminase gene into the construct. In such therapy, the three enzymes need only two innocuous prodrugs, 5 -FC and GCV; as a result, 5 -FU may not be necessary with UT gene therapy. Moreover, cytosine deaminase plus TK fusion gene therapy has been reported to increase the radiosensitization effect beyond that observed with each system alone. 12 Thus, the therapeutic effect of these combined modalities can be further enhanced by coupling them with radiotherapy.
In a clinical study, local endoscopic injection of a biological response modifier combined with radiation has been reported to be useful and safe for the treatment of advanced esophageal cancer. 33 As local endoscopic injection is used in clinical UT gene therapy, tumorspecific delivery is not a vital issue. However, it is still necessary to achieve tumor-specific delivery in order to apply this therapy to other tumor models. A promising strategy is to use tumor-specific promoters to drive genes of interest. Previous reports demonstrate that it is good strategy to control encoding genes with tumor-specific promoters such as CEA promoter 34 or Midkine promoter. 27 Replication -competent E1B -attenuated adenovirus vector ( ONYX -015 ), 35 which replicates selectively in tumor cells lacking normal p53 function, is also a good candidate for UT fusion gene delivery. Among recent cancer gene therapy reports, adenoviral -mediated p53 gene transfer is frequently used, together with cis -dichloro -diammineplatinum( II ) administration.
36 ± 38 AxCA.UT gene therapy is applied in clinical trials combined with standard multimodality treatment such as 5 -FU, cisplatinum, and radiation therapy. On the basis of these premises, we believe that the AxCA.UT gene therapy described here may generate a significant increase in the therapeutic index when used clinically.
CONCLUSION
We describe an adenoviral vector used to deliver fusion genes containing a suicide gene to esophageal carcinoma cells. This strategy may be useful in the development of various combinations using a variety of therapeutic transgenes ( i.e., HSV-TK, p53, cytokine deaminase, and several cytokines ). AxCA.UT infection combined with 5 -FU plus GCV treatment is applicable in future clinical trials and is a good candidate for additional multimodality treatment of esophageal cancer. 
